Registry Study of Pharmacotherapy and Clinical Outcomes in Elderly Patients With Coronary Heart Disease (PHARM-ageing)

Launched by BEIJING ANZHEN HOSPITAL · Feb 9, 2022

Keywords

ClinConnect Summary

The PHARM-ageing study is a research project that aims to understand how different medications affect the health of elderly patients with coronary heart disease, which is a condition that affects the heart and blood vessels. The study will look at how these treatments influence the patients' overall health and well-being. This trial is not yet recruiting participants, but it will focus on individuals aged 65 and older who have been diagnosed with coronary heart disease in the hospital.

To be eligible for the study, participants must give their consent and be able to communicate effectively with the researchers. Unfortunately, those with serious mental disorders or those who cannot provide important medical information may not be able to join. If you or a loved one qualify, participating in this study could help improve understanding of how to best treat elderly patients with heart issues. Participants will be monitored for their health outcomes while receiving medication, contributing valuable information to improve heart care in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Informed consent has been signed
• • Patients diagnosed in our hospital with coronary heart disease
• • Age ≥65 years
• Exclusion Criteria:
• • Severe lack of important information such as history of previous medication, history of previous disease, history of surgery.
• • Mental disorders, or inability to communicate effectively with researchers, or failure to comply with research protocols.